Biomarker News and Research RSS Feed - Biomarker News and Research

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Commonwealth announces availability of new ELISA-based blood test to quickly and reliably diagnose IBS

Commonwealth Laboratories, Inc. announced today the availability of IBSchek, a new blood test designed to help physicians quickly and reliably diagnose Irritable Bowel Syndrome (IBS). [More]
Simple blood tests diagnose irritable bowel syndrome quickly and accurately

Simple blood tests diagnose irritable bowel syndrome quickly and accurately

Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist. [More]
Denali launched to discover, develop effective medicines for neurodegenerative diseases

Denali launched to discover, develop effective medicines for neurodegenerative diseases

Denali Therapeutics Inc., a new biotechnology company focused on developing effective therapies for neurodegenerative diseases, announced today that it has launched with an initial investment commitment of $217 million. [More]
Workplace mindfulness-based intervention reduces stress levels of employees

Workplace mindfulness-based intervention reduces stress levels of employees

A study by researchers at The Ohio State University Wexner Medical Center found that a workplace mindfulness-based intervention reduced stress levels of employees exposed to a highly stressful occupational environment. [More]
New method may help determine potential indicator of stress, neurological disorders

New method may help determine potential indicator of stress, neurological disorders

A research collaboration between the universities of Oslo and Aarhus has resulted in the development of a new method with diagnostic potential. The new method that combines phase extraction with an enzymatic reaction may eventually be used for an improved and faster screening analysis of isatin as a potential indicator of stress and neurological disorders. [More]
Workplace mindfulness-based intervention reduces stress levels and risk of burnout

Workplace mindfulness-based intervention reduces stress levels and risk of burnout

A study by researchers at The Ohio State University Wexner Medical Center found that a workplace mindfulness-based intervention reduced stress levels of employees exposed to a highly stressful occupational environment. [More]
Removing bacterial biofilms could help prevent and treat colon cancers, study suggests

Removing bacterial biofilms could help prevent and treat colon cancers, study suggests

A team led by scientists at The Scripps Research Institute and Johns Hopkins University School of Medicine has uncovered a big clue to how bacteria may promote some colon cancers. [More]
Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Heather Wakelee, MD, is the recipient of the 2015 ECOG-ACRIN Young Investigator Award, the ECOG-ACRIN Cancer Research Group announced today. Dr. Wakelee is associate professor of medicine in the Division of Oncology at the Stanford University School of Medicine in Stanford, Calif. [More]
First patient receives new 'resistance-busting' experimental skin cancer drug

First patient receives new 'resistance-busting' experimental skin cancer drug

A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial. The patient has received a new panRAF inhibitor - a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types. [More]
Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014. [More]
CANCER-ID consortium aims to set up standard procedures for clinical validation of blood-based biomarkers

CANCER-ID consortium aims to set up standard procedures for clinical validation of blood-based biomarkers

Blood-based biomarkers such as circulating tumor cells (CTCs), circulating free DNA (cfDNA), circulating tumor DNA (ctDNA) and microRNAs (miRNAs) are potential indicators for the tumor burden of patients living with cancer. [More]
International study finds that two-week diet swap for African-Americans may lower colon cancer risk

International study finds that two-week diet swap for African-Americans may lower colon cancer risk

African-Americans and Africans who swapped their typical diets for just two weeks similarly exchanged their respective risks of colon cancer as reflected by alterations of their gut bacteria, according to an international study led by researchers at the University of Pittsburgh School of Medicine published online today in Nature Communications. [More]
Dramatic effects on colon cancer risk for Americans and Africans when diet swapped

Dramatic effects on colon cancer risk for Americans and Africans when diet swapped

Scientists have found dramatic effects on risk factors for colon cancer when American and African volunteers swapped diets for just two weeks. [More]
PCDx test performs better than FoundationOne test in clinical study

PCDx test performs better than FoundationOne test in clinical study

Data from a small cohort published OncoTargets and Therapy today shows that the Paradigm Cancer Diagnostic Test (PCDx) performed better than Foundation Medicine's FoundationOne test across a number of key clinical variables, including turnaround time (TAT) and clinically actionable biomarker targets. [More]
Vermillion reports expanded medical policy coverage of OVA1 test

Vermillion reports expanded medical policy coverage of OVA1 test

Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, today announced expanded medical policy coverage of its OVA1 test, following Blue Cross Blue Shield of Michigan's recent decision to include OVA1 in its medical policy guidelines. [More]
Molecular Health granted European patent for novel Erythropoietin receptor

Molecular Health granted European patent for novel Erythropoietin receptor

Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth. [More]

First CE marked FGF23 ELISA assay launched at Biomedica Immunoassays

The biomarker specialists at Biomedica Immunoassays, announced the launch of the first CE marked FGF23 (C-terminal) ELISA assay which specifically detects both intact and C-terminal fragments of FGF23 in human serum and plasma. The FGF23 ELISA assay complements the existing Biomedica assays directed against chronic kidney disease - mineral and bone disorder (CKD-MBD) in a growing collection. [More]
Purdue University study sheds light on how decitabine drug reverses cell damage

Purdue University study sheds light on how decitabine drug reverses cell damage

A Purdue University study sheds light on how cell damage is reversed by the cancer drug decitabine and identifies a potential biomarker that could indicate a patient's stage of cancer and response to treatment. [More]
Sysmex Inostics to offer OncoBEAM CLIA laboratory services in Germany, Austria and Switzerland

Sysmex Inostics to offer OncoBEAM CLIA laboratory services in Germany, Austria and Switzerland

Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced that they have signed an exclusive distributor agreement with IndivuTest GmbH, and its parent company Indivumed GmbH, a cancer research company focused on the development of individualized cancer diagnostics and therapies. [More]
Study opens door to new treatment for hard-to-treat asthmatic children

Study opens door to new treatment for hard-to-treat asthmatic children

Researchers have identified a biological basis for asthmatic children who do not respond well to corticosteroid treatment – currently the most effective treatment for chronic asthma and acute asthma attack. [More]
Advertisement
Advertisement